key: cord-0831628-kacsdkr5
authors: de la Cruz‐Benito, B; Lázaro‐del Campo, P; Ramírez‐López, A; de Soto‐Álvarez, T; Sánchez‐Vadillo, I; García‐Pérez, E; Dos Santos‐Ortas, A; Humala‐Barbier, K; López‐de la Guía, A; Casado‐Abad, G; Jiménez‐Yuste, V; Canales‐Albendea, MA
title: Managing the front‐line treatment for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma during the COVID‐19 outbreak
date: 2020-08-06
journal: Br J Haematol
DOI: 10.1111/bjh.17066
sha: 7df54aeca6579b2e247992a29b6ddf919315e87a
doc_id: 831628
cord_uid: kacsdkr5

The COVID‐19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment that represent a vulnerable population for SARS‐CoV‐2 infection. Aggressive lymphoid neoplasms, such as diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed so as to minimize risk of SARS‐CoV‐2 infection while continuing haematological treatment. In this report, we analyse the management of front‐line therapy in 18 patients during COVID‐19 outbreak, as well as the results of the implemented measures in their outcome.

The COVID-19 pandemic has dramatically challenged care for cancer patients. Among them, those with haematological malignancies, particularly lymphoid neoplasms, represent one of the most vulnerable populations. In addition to the immune deregulation caused by lymphoma, many patients receive therapy that causes profound immune suppression. At the beginning of the current outbreak, our main worries were the implications of treatment delay on outcomes in this population, the risks of continuing treatment, how to protect our patients, the threat of infection among these patients and, lastly, how long the outbreak of COVID-19 would last.

At the beginning, few guidelines regarding the management of lymphoid malignancies during COVID-19 pandemic were available (Perini GF et al (2020) , Di Ciaccio P et al (2020) ).

As treatment of patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) cannot be delayed without having detrimental effects on the outcomes, we had to adapt our clinical practices to cope with these concerns. We have conducted an analysis on the effect of COVID-19 pandemic in the front-line therapy of patients with DLBCL and HGBL.

This article is protected by copyright. All rights reserved All patients who were receiving front-line treatment for DLBCL and HGBL at La Paz University Hospital from March 1 to May 31, 2020, were included in this analysis. Patients under salvage therapy or in follow-up after the end of treatment were not included.

Due to epidemiological context, several specific measures were adopted in order to minimize risk of SARS-CoV-2 infection in these patients as well as to guarantee the continuation of their therapy. In order to keep our installations as a COVID-19-free area, a checklist of symptoms and temperature screening was done before accessing to the outpatient area for patients who should be necessarily attended. No entry was allowed for any individual with suspicion of COVID-19 and no visitors (i.e. family, companion) were permitted. Follow-up was done remotely by telemedicine in patients who were not receiving active treatment, if possible.

Immune-chemotherapy treatments were not postponed exclusively because of pandemic context in any patient. As a protective measure, patients were tested for SARS-CoV-2 by nasopharyngeal swab before each new treatment.

R-CHOP was the chosen treatment for patients with DLBCL, administered as an outpatient regimen. HGBL were treated with intensive therapy such as dose-adjusted EPOCH-(R) (DA-EPOCH-R), which require hospitalization. Elderly patients received attenuated regimens (Rmini-CHOP).

Primary prophylaxis with G-CSF was taken in most of the patients, as a way of prevention from neutropenia.

A total of 18 patients with DLBCL and HGBL were attended during the period of time of the study in our hospital, including 7 women and 11 men. The median age was 57 years (range 27-82). The clinical and demographic characteristics of these patients are summarized in table 1.

This article is protected by copyright. All rights reserved Only 3 patients have a different diagnosis from DLBCL: one was diagnosed with plasmablastic lymphoma, while the other 2 had HGBL, not otherwise specified (NOS). Among the patients with DLBCL diagnosis, one of them was transformed from a splenic marginal zone lymphoma.

Regarding treatment, 3 patients received DA-EPOCH (only 1 of them combined with Rituximab, because of plasmablastic origin in patient 2 and lack of CD20 expression in patient 3), 11 were treated with R-CHOP (combined with bispecific CD3/CD20 monoclonal antibody in one patient under clinical trial) and 4 received R-mini-CHOP because of their age.

Primary prophylaxis with G-CSF was administered in 7 patients, since day 8-10 of cycle for 3-5 days. Five of them started first cycle of chemotherapy after the lockdown. If chemotherapy had already been administered before COVID-19 outbreak, prophylactic G-CSF was only provided to patients who had developed neutropenia before (secondary prophylaxis). Patients in treatment with DA-EPOCH regimen also received prophylactic G-CSF as it is part of the protocol.

Neutropenic fever was only observed in patient 10, on day 10 of first cycle of chemotherapy while she was receiving G-CSF. Although our patient did not refer any other symptom apart from fever, several microbiological tests (including blood stream cultures, urine culture and SARS-CoV-2 PCR) were done. COVID-19 was diagnosed at that moment and treatment with hydroxychloroquine and azithromycin was initiated. Because of the viral diagnosis, thoracic CT was performed, showing bilateral ground-glass opacities and two consolidations suggestive of viral disease. Antibiotic treatment with amoxicillin-clavulanic acid was added, requiring an escalation strategy because of fever persistence, sequentially to levofloxacin, cefepime and, finally, to meropenem and linezolid, reaching fever defervescence. Patient had stable hemodynamic situation without oxygen therapy requirement. Table 2 shows analytical evolution since administration of the first cycle of treatment and during SARS-COV-2 infection until recovery. Severe neutropenia (grade 4) and lymphopenia (grade 4) were present at the moment of COVID diagnosis, with a progressive increase in the following days after administration of G-CSF from day +10 to +16 and from day +24 to +26. C-reactive protein was also monitored, reaching a peak value on day +14.

This article is protected by copyright. All rights reserved sobreinfection. No other microbiological isolation was detected. Second chemotherapy cycle had to be postponed 8 days until resolution of infection, confirmed by 2 consecutively negative SARS-CoV-2 PCR prior to treatment administration.

We did not register any other febrile neutropenia in our cohort.

As lymphopenia has been described as a common finding during SARS-CoV-2 infection, we analysed minimum lymphocyte count among our patients during the time of study.

Lymphopenia (defined as <1.1x10 9 lymphocytes/L) was observed in 16 patients. A minimum of 0.05x10 9 lymphocytes/L was detected in patient 10, simultaneously to COVID-19 diagnosis, as shown in table 2. Among patients without lymphopenia, 50% of them were treated with R-mini-CHOP.

In the last three months, our hospital has dramatically suffered the impact of COVID-19 outbreak. In this scenario, our goal was to achieve a balance between risk and benefit for the patients with lymphoid malignancies, one of the most vulnerable populations for SARS-CoV-2 infection. Shah et al has recently described the incidence of lymphoid malignancies among patients with haematological diseases and COVID-19. In their cohort, 77% of infected patients were diagnosed of lymphoid malignancy or plasma cell dyscrasia, a similar proportion than in our centre. Because of that, and especially considering patients with aggressive disease that requires early treatment, our clinical practice was redesigned to optimize benefit while minimizing toxicity, viral exposure risk, and resource utilization , , Weinkove R et al (2020) ).

R-CHOP continues to be the standard of care for young DLBCL patients while R-mini-CHOP with growth factor support is the recommended strategy for older and unfit patients.

Avoidance of intensified regimens during COVID-19 outbreak, such as DA-EPOCH-R, usually administered in HGBL, has been recommended in recent guidelines (Perini GF et al (2020) , Di Ciaccio P et al (2020) ), in order to reduce immunosuppression and potential complications of the patients. In contrast, our centre decided to keep these regimens, giving

This article is protected by copyright. All rights reserved priority to reaching the best disease control and outcome. The measurements implemented to prevent COVID-19 were effective to allow continuing treatment. It should be noted that, unlike a recent publication that describes intensive active treatment as a risk factor for infection (Shah et al (2020) ), only one of our patients developed a mild COVID-19 while receiving front-line therapy. No patients undergoing intensified treatments were infected by SARS-CoV-2. Likewise, Robilotti et al (2020) have recently stated that active chemotherapy in the 30 days prior to COVID-19 does not confer any risk for disease severity, although they show a 12% of mortality among cancer patients because of SARS-CoV-2 infection, lower than what have been previously published. Our study results suggest that, despite maintaining aggressive treatments, it is possible to keep our patients free of COVID-19. However, further studies are needed to clarify the importance of prior or active chemotherapy in COVID-19 evolution.

Lymphopenia is a common finding, not only in patients with lymphoma but also in infection by SARS-CoV-2, with a predisposing role to severe viral infection (Terpos E et al (2020) , Tan L et al (2020) ), although its definite paper has not been established and some new investigations show a probable association between lymphopenia and better outcome (Shah et al (2020) ). It is noteworthy that minimum lymphocyte count was registered in our cohort in the only patient who was infected by SARS-CoV-2, simultaneously to the moment of COVID-19 diagnosis. Despite the probable relationship between grade of lymphopenia and severity of COVID-19, our patient presented a favourable evolution. So far, no investigation has been done analysing the importance of lymphopenia as a predictive factor of severe SARS-CoV-2 infection in patients with previous lymphopenia.

It is remarkable that only one infectious event appeared during the study period in our series, which means a very low incidence of febrile neutropenia. No patient required inpatient management, except the one with COVID-19, allowing limited visits of the patients to the hospital. Following international recommendations that advocate for the use of prophylactic G-CSF, in order to minimize the risk of febrile neutropenia, we started this practice in the majority of patients. Although these recommendations had only empiric support, they may have influenced the low incidence of COVID-19 in our cohort.

This article is protected by copyright. All rights reserved

Despite new studies are needed to clarify the behaviour of COVID-19 among patients with lymphoid malignancies, we can conclude that successful front-line therapy is possible in these patients during a pandemic outbreak. These results may be possible as a consequence of a mixture of hygiene measurements, prophylactic actions and clinician and patient awareness. As new SARS-CoV-2 outbreaks are expected, it is important to examine outcomes and learn from these efforts in order to guide health professionals and contribute to future progress.

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic

How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation

Determinants of Severity in Cancer Patients with COVID-19 Illness. medRxiv

Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Hematological findings and complications of COVID-19

Managing haematology and oncology patients during the COVID-19 pandemic

Care of haematology patients in a COVID-19 epidemic

Assessing the impact of lockdown: Fresh challenges for the care of haematology patients in the COVID-19 pandemic

This article is protected by copyright. All rights reserved